Olympia Pharmaceuticals Adds Gonadorelin to Its Growing Men’s Hormone Portfolio
A synthetic copy of the hormone signal that prompts the body to make testosterone, the new 1 mg/mL formulation is now
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
ORLANDO, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) — Olympia Pharmaceuticals, an FDA-registered 503B outsourcing facility and 503A pharmacy, today announced the availability of its new Gonadorelin 1 mg/mL injection. Expanding Olympia’s suite of men’s hormone offerings, the compounded formulation gives healthcare providers a synthetic copy of the hormone signal that sets testosterone production in motion.
Gonadorelin stimulates the release of luteinizing and follicle-stimulating hormones, which signal the testes to produce testosterone. For appropriately selected patients, it may support the body’s own testosterone production as part of an individualized hormone optimization plan.
“As we continue to expand our hormone portfolio, we’re focused on what providers are asking us to keep in stock,” said Joshua Fritzler, President of Olympia Pharmaceuticals. “Adding Gonadorelin gives practices another specialized option from a pharmacy partner they already rely on as they continue to build out their men’s health programs.”
Supplied in a 5 mL vial at a concentration of 1 mg/mL for intravenous (IV), intramuscular (IM), or subcutaneous (SQ) use, Olympia’s Gonadorelin injection is a ready-to-use solution that requires no reconstitution before administration. Vials are stored under refrigeration and protected from light.
“Hormone protocols depend on consistency, and that starts with the formulation itself,” said Christopher Lorich, PharmD, pharmacist at Olympia Pharmaceuticals. “Gonadorelin is a synthetic form of a hormone the body already uses to signal for testosterone production, and having it in a ready-to-use vial takes a variable out of the prescriber’s protocol.”
The new Gonadorelin injection is now available to order across 49 states for clinical office use and patient-specific prescriptions.
“Men’s health used to be something a practice added on. For a lot of our accounts, it is now the reason patients walk in,” said Hayden Goldman, Director of Commercial Sales at Olympia Pharmaceuticals. “We want to be the pharmacy that keeps up with that.”
The addition of Gonadorelin extends Olympia’s hormone offerings, giving providers access to a wider range of compounded therapies under one roof. The company continues to build out its 503B catalog with specialty formulations that practices can order alongside the products they already stock.
For more information about Olympia Pharmaceuticals, visit olympiapharmacy.com or call 407-673-2222.
About Olympia Pharmaceuticals
Olympia Pharmaceuticals is a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility and 503A pharmacy supporting both patient-specific and office-use needs across the U.S. Co-founded by Stan and Naomi Loomis, the team is made up of pharmacy technicians, pharmacists, quality personnel, and engineers, creating an educated and experienced staff knowledgeable in all facets of pharmacy production. As an FDA-registered outsourcing facility, Olympia offers compounded medications to 49 states for both office use and patient prescriptions. Olympia specializes in weight loss, dermatology, IV nutritional therapy, erectile dysfunction, and more.
Media Contact
Daniele Spring
Uproar by Moburst for Olympia Pharmaceuticals
Daniele.Spring@Moburst.com
